TrialThe Lancet. Respiratory medicine2023

Efficacy and safety of baricitinib or ravulizumab in adult patients with severe COVID-19 (TACTIC-R): a randomised, parallel-arm, open-label, phase 4 trial.

Frances C Hall et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.